Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Investor Presentation (June 2024)
28 slides from Amplia Therapeutics's investor presentation, Jun 11, 2024
Slide 1: Presentation and Webinar ASX release
ABN 16 165 160 841 ASX RELEASE 11 June 2024 PRESENTATION AND WEBINAR Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”) is pleased to announce that the Company’s CEO and Managing Director Dr Chris Burns is presenting an introduction to the Company as part of a
Slide 2: Focal Adhesion Kinase Inhibitors: Targeting Cancer and Fibrosis
lO ilies: IXxmol itors: inase Inh Cancer and Fibrosis ion K Focal Adhes ing Target June 2024 ampliatx.com | @ampliatx
Slide 3: Important Notice and Disclaimer
For personal use only Important Notice and Disclaimer This presentation (Presentation) contains summary information about Amplia Therapeutics Limited ACN 165 160 841 and its subsidiaries (the Company or Amplia) which is current as at 31 Mar 2024, By attending an investor presentation or briefing, or
Slide 4: Outline
Outline Section One Corporate Overview Section Two FAK and Narmafotinib Section Three Narmafotinib in Solid Tumours Section Four Narmafotinib in the Clinic Section Five Summary
Slide 5: Section One: Corporate Overview
Section One Corporate Overview lAsmplia TH eGane A Pees UsT, JoCes:
Slide 6: Company Overview
For personal use only COMPANY OVERVIEW © ASX:ATX e Headquartered in Melbourne, Australia e Market capitalization: A$19.6M e AU Institutional Investors include Platinum, Blueflag, Acorn Capital, Pengana Capital lasmplia THERAPEUTICS BOARD OF DIRECTORS Warwick Tong MB ChB MPP GAICD Chair Senior and ex
Slide 7: Highlights
For personal use only HIGHLIGHTS © Clinical trial in advanced pancreatic cancer underway e Interim readout planned for Q3 2024 ¢ Preliminary signs of efficacy Lean, experienced drug development team e Network of experienced consultants and contractors lAxmplia THERAPEUTICS Open IND for narmafotinib
Slide 8: Pipeline
PIPELINE ts Drug Target Indication Preclinical INDenabling Phase1 Phase 2 Late Phase Status Pancreatic Cancer 7 >) Narmafotinib (AMP945) FAK (+Gemeitabine/Abraxane) _ | IACCE > Enrolling c 4 3 : |) Cl Pancreatic Cancer o (+FOLFIRINOX ) IND approved n =) : ' _ Ovarian Cancer In planning © 5 Other sol
Slide 9: Milestones
MILESTONES 2 c fo) & Pancreatic ACCENT Commence 3 Interim FOLFIRINOX a Cancer Analysis Trial in US c jo} n pd 8 S pale Commence Clinical Trial Partnering lAsmoplia THERAPEUTICS ACCENT Trial Complete Phase 2b/3 Planning Regional Licensing Deal
Slide 10: Section Two: FAK and Narmafotinib
Section Two FAK and Narmafotinib
Slide 11: Role of FAK in Cancer
For personal use only ROLE OF FAK IN CANCER lAsmplia THERAPEUTICS FAK involvement in both cell intrinsic and extrinsic effects allows an inhibitor to target multiple cancer pathways. A FAK inhibitor is well placed to work in combination with various combination therapies and in multiple indications.
Slide 12: Potential for Combination with Targeted Agents
i POTENTIAL FOR COMBINATION WITH (°° TARGETED AGENTS Literature evidence for synergistic or additive combinations with: > s ¢ Raf/Mek inhibitors ® ¢ Kras inhibitors outs beet i 3 — recept — kinases = ¢ Hippo Pathway inhibitors g oP <s 9 ¢ 1/O agents Pre eee aS \ a integrin D © anti PD-1 and PD-L1 \
Slide 13: Narmafotinib (AMP945)
For personal use only “Xxmpli NARMAFOTINIB (AMP945) ronan ries Drug-like, ATP-competitive, small molecule 5 we : electivity Highly potent and selective Highly selective for FAK Excellent PK; once-a-day dosing Minimal risk for drug-drug interactions Best-in-class profile Narmafotinib FAK Activity Dru
Slide 14: Section Three: Narmafotinib in Solid Tumours
Section Three Narmafotinib in Solid Tumours
Slide 15: Narmafotinib Activity In Vivo
For personal use only NARMAFOTINIB ACTIVITY IN VIVO Reduces total Increases Survival collagen Ps0.05 Probability of Survival 25 50 75 100 125 150 Days post-treatment a g Dp an < 5 8 = a g i 2 Vehicle Narmafotinib FOLFIRINOX Probability of Survival Garvan Institute of Medical Research T T 1 25 50 75
Slide 16: Narmafotinib Increases Immuno-Reactivity of TME
For personal use only Frame Lab (Uni of Edinburgh) NARMAFOTINIB INCREASES IMMUNO- “xmplia REACTIVITY OF TME In vivo, narmafotinib treatment reduces tumor-infiltrating MDSCs* and tumor-associated macrophages and increases CD8+ T-cells off Macrophages cp206* PD-L1* PD-L2* ee Pepe Troge Macrophages * 4
Slide 17: Section Four: Narmafotinib in the Clinic
Section Four Narmafotinib in the Clinic
Slide 18: Phase 1 Trial of Narmafotinib
lAsmplia PHASE 1 TRIAL OF NARMAFOTINIB Peale Trial Execution Recruited 56 healthy volunteers aged 18 - 65 Single and multiple ascending doses Single site in Melbourne, Australia Completed 2021 Summary of Outcomes Safe and well-tolerated at all doses tested For personal use only identified safety tre
Slide 19: Pancreatic Cancer
For personal use only PANCREATIC CANCER Increasing Prevalence Est. 64,000 diagnoses and 50,000 deaths in US this year* 4,500 were diagnosed in 2023 in AU in 2023** * American Cancer Society (link) “ Cancer Australia (link) 5 year survival Difficult-to-treat: typically detected late in disease progre
Slide 20: ACCENT Phase 1b/2a Clinical Trial
ACCENT PHASE 1B/2A CLINICAL TRIAL “xmoplia First-line therapy Patients with non-resectable or metastatic pancreatic cancer Overall Endpoints: Intermittent dosing of narmafotinib between normal ° Primary chemotherapeutic doses of gemcitabine/nab-paclitaxel Bpobic cUvciles oD ae i © Duration of respon
Slide 21: ACCENT Trial Design
ACCENT TRIAL DESIGN “xmplia Dose Interim —o Phase 1b Phase 2a Phase 2a (cont) > 14 patients 26 patients 24 patients For personal use only C) le ®@ COMPLETED RECRUITING 20
Slide 22: ACCENT Phase 1b Summary
For personal use only lAsmplia ACCENT PHASE 1B SUMMARY THERAPEUTICS 3 Cohorts (100 mg, 200 mg, 400 mg; QD) Safe and well tolerated © All patients elected to stay on drug post cycle 1 © One DLT: uncontrolled nausea © Fatigue (Gr 3 or below) in more than 1 patient likely drug related Comparison to his
Slide 23: ACCENT Phase 1b Summary
For personal use only ACCENT PHASE 1B SUMMARY Patient Duration on ACCENT trial (as at May 2024) . “ : —ewe OED, : is : r i 5 PR PSS Se 2 z x i cls: H : H } @Withdrawn __s |= (CCE i Ongoing (Ee lll EEG t t t t 1 150 200 250 300 350 Duration of Treatment (days) [= 100mg mm 200mg mm 400mg->100mg mM 400
Slide 24: For personal use only
For personal use only
Slide 25: Opportunity Summary
For personal use only OPPORTUNITY SUMMARY Combinations in pancreatic cancer Combinations in ovarian cancer lAsmoplia THERAPEUTICS Preclinical evidence in other solid tumors Gemcitabine and Abraxane (ACCENT trial) FOLFIRINOX (US trial with open IND) Platinum resistant disease Maintenance therapy post
Slide 26: Competitive Advantage
For personal use only COMPETITIVE ADVANTAGE Narmafotinib Defactinib (Verastem) Ifebemtinib (Inxmed) GSK2256098 x) / v 9 Good DDI Clinical Notes Safe and well tolerated Recent success in Phase 2 LGSOC Drug related, off- target adverse events noted First generation FAKi Issues with DDI and MTD lower t
Slide 27: Highlights
For personal use only i HIGHLIGHTS dxmoplia ® Best-in-class Orphan drug designation in pancreatic cancer and IPF (@) Demonstrated safety and tolerability in healthy volunteers and patient population Preliminary signs of efficacy in pancreatic cancer Open IND Strong IP position MU 25
Slide 28: For personal use only
LAM Mplio Tob EeRwAR PSE TGS: Chris Burns PhD GAICD Amplia Therapeutics Limited Reoane ne ABN 16 165160 841 chris@ampliatx.com ASX: ATX iy info@ampliatx.com ampliatx.com | @ampliatx ihe
Amplia Therapeutics — Investor Presentation (June 2024) on 6ix